



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

Pain-relieving effects of the mTOR  
inhibitor in the anterior cingulate  
cortex of neuropathic rats

Sun Woo Um

Department of Medical Science

The Graduate School, Yonsei University

# Pain-relieving effects of the mTOR inhibitor in the anterior cingulate cortex of neuropathic rats

Sun Woo Um

Department of Medical Science

The Graduate School, Yonsei University

# Pain-relieving effects of the mTOR inhibitor in the anterior cingulate cortex of neuropathic rats

Directed by Professor Bae Hwan Lee

The Master's Thesis  
submitted to the Department of Medical Science,  
the Graduate School of Yonsei University  
in partial fulfillment of the requirements for the degree of  
Master of Medical Science

Sun Woo Um

June 2018

This certifies that the Master's Thesis  
of Sun Woo Um is approved.

---

Thesis Supervisor : Bae Hwan Lee

---

Thesis Committee Member#1 : Joong Woo Leem

---

Thesis Committee Member#2 : Tae Dong Kweon

The Graduate School  
Yonsei University

June 2018

## ACKNOWLEDGEMENTS

대학원 입학부터 졸업까지 쉽지 않은 결정이었지만 이렇게 학위논문을 마무리할 수 있게 되어 너무 기쁩니다. 공부와 실험 뿐만 아니라 다양한 경험을 할 수 있었던 대학원에서의 시간이 저에게는 너무 큰 자산이 되었습니다. 너무 많은 분들의 도움으로 여기까지 올 수 있었습니다.

먼저 학위논문을 완료하기까지 많은 도움을 주셨던 이배환 지도 교수님께 감사드립니다. 작은 부분까지 세심하게 챙겨주시고 항상 좋은 기운을 주셔서 이처럼 학위논문을 완성할 수 있게 되었습니다. 그리고 바쁘신 와중에도 시간 내시어 자문 심사부터 제 연구에 많은 관심을 가지고 조언해 주신 임중우 교수님과 권태동 교수님께도 깊은 감사의 말씀을 전합니다. 실험실에서 함께 생활하며 각자 연구에 바쁜 와중에도 많은 도움을 주며 힘이 되었던 효진이, 민지, 경민이 그리고 송연이에게도 진심으로 고마움을 전합니다. 그리고 항상 많은 조언과 격려를 해주신 이경희 선생님, 김은정 선생님, 사영희 선생님께도 감사드립니다.

마지막으로 항상 힘들어 할 때마다 격려해주고 인생의 큰 버팀목이 되어주는 우리 엄마, 언제나 든든하게 내 편이 되어주는 멋진 우리 오빠 너무너무 감사합니다. 어떤 일이 있어도 내편이 되어주는 우리 가족 뭐라 말로 표현할 수 없을 만큼 너무 고맙고 사랑합니다. 지금처럼 언제나 건강하고 즐거운 가족으로 함께 했으면 좋겠습니다.

일일이 기재하지 못했지만 학교생활에 그리고 제 인생에 많은 도움을 주신 많은 분들께 이 기회를 통해 감사의 말씀을 전합니다.

2018년 6월  
엄선우 드림

# TABLE OF CONTENTS

<b>ABSTRACT</b> .....	1
<b>I. INTRODUCTION</b> .....	3
<b>II. MATERIALS AND METHODS</b> .....	7
1. Neuropathic Pain Model .....	7
A. Animals .....	7
B. Surgical Procedure .....	7
2. Cannula Implantation .....	8
3. Drug Microinjection into the ACC .....	8
4. Behavior Test .....	9
A. Measuring Response Withdrawal Threshold .....	9
B. Changes of Mechanical Allodynia after Microinjection .....	9
5. Western Blot Analysis .....	10
6. Histology .....	11
A. Immunofluorescence Staining .....	11
B. Image Analysis .....	12
7. Optical Imaging .....	13
8. Statistical Analysis .....	15

<b>III. RESULTS</b> .....	16
1. Development of Mechanical Allodynia Induced by Nerve Injury ..	16
2. Nerve Injury Activates mTOR Signaling in the ACC .....	19
3. Microinjection of Rapamycin into the ACC Diminishes Mechanical Allodynia After Nerve Injury .....	22
4. Microinjection of Rapamycin into the ACC Blocks Activation of mTOR and its Downstream Effectors in the ACC After Nerve Injury .....	25
5. Inhibition of mTOR Suppresses Synaptic Protein Expression in the ACC After Nerve Injury .....	28
6. Inhibition of mTOR Reduces Excitability in the ACC Induced by Peripheral Stimulation .....	33
<b>IV. DISCUSSION</b> .....	39
<b>V. CONCLUSION</b> .....	43
<b>REFERENCES</b> .....	44
<b>ABSTRACT (IN KOREAN)</b> .....	50

## LIST OF FIGURES

Figure 1. Electronic von Frey Test and Development of Mechanical Allodynia .....	17
Figure 2. Activation of mTOR and its Downstream Effectors in the ACC after Nerve Injury .....	20
Figure 3. Microinjection of Rapamycin Attenuates Mechanical Hypersensitivity .....	23
Figure 4. Microinjection of Rapamycin into the ACC Suppresses Activation of mTOR and its Downstream Effectors after Nerve Injury .....	26
Figure 5. Synaptic Protein Expression After Inhibition of mTOR Signaling in the ACC .....	29
Figure 6. Changes in Optical Signals in the ACC .....	35

## ABSTRACT

Pain-relieving effects of the mTOR inhibitor in the anterior cingulate cortex of neuropathic rats

Sun Woo Um

*Department of Medical Science  
The Graduate School, Yonsei University*

(Directed by Professor Bae Hwan Lee)

The anterior cingulate cortex (ACC) is a well-known brain area that is associated with pain perception. Previous studies reported that the ACC has a specific role in the emotional processing of pain. Chronic pain is characterized by long-term potentiation that is induced in pain pathways and contributes to hyperalgesia caused by peripheral nerve injury. The mammalian target of rapamycin (mTOR) signaling, which is involved in synaptic protein synthesis, could be a key factor controlling long-term potentiation in neuropathic pain conditions. Until now, there have been no reports that studied the role of mTOR signaling in the ACC involved in neuropathic pain. Therefore, this study was conducted to determine the relationship of mTOR signaling in the ACC and neuropathic pain. Male Sprague-Dawley rats were subjected to nerve injury under pentobarbital anesthesia and microinjected with rapamycin, an mTOR inhibitor, into the ACC on postoperative days (PODs) 7. A behavioral test was performed to

evaluate mechanical allodynia and optical imaging was conducted to observe the neuronal responses of the ACC to peripheral stimulation. Inhibition of mTOR by rapamycin reduced mechanical allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved in excitatory signaling, thereby reduced neuropathic pain-induced synaptic plasticity. These results suggest that inhibiting mTOR activity by rapamycin into the ACC could serve as a new strategy for treating or managing neuropathic pain before it develops into chronic pain.

---

Key words: neuropathic pain, mammalian target of rapamycin (mTOR), anterior cingulate cortex (ACC), rapamycin, synaptic plasticity

Pain-relieving effects of the mTOR inhibitor in the anterior cingulate  
cortex of neuropathic rats

Sun Woo Um

*Department of Medical Science  
The Graduate School, Yonsei University*

(Directed by Professor Bae Hwan Lee)

## I. INTRODUCTION

Neuropathic pain is induced by various causes, including tissue or nerve damage, and is characterized by symptoms of spontaneous pain, allodynia, and hyperalgesia.<sup>1</sup> Currently, many therapies such as antidepressants and antiepileptics are used to treat neuropathic pain, but these medications have side effects and are not always effective.<sup>2-4</sup> Thus, the management of neuropathic pain remains difficult. In the brain, cortical areas that process information related to pain are known as the “pain matrix”, which includes the anterior cingulate cortex (ACC), insular cortex (IC), thalamus, somatosensory cortex, and prefrontal cortex.<sup>1,2,5</sup> Among these regions, the ACC is the main area associated with pain perception,<sup>6</sup> and accumulating evidence implicates the involvement of the ACC in the emotion processing of pain.<sup>7,8</sup>

Long-term potentiation (LTP) induced by repeated abnormal sensory signaling after peripheral nerve injury is a primary feature of chronic pain in the central nervous system, and the reinforcement of synaptic transmission is a core cellular mechanism of chronic pain.<sup>9</sup> Such long-term synaptic plasticity or central

sensitization in the spinal cord and cortical areas is known to contribute to chronic pain.<sup>10</sup> In addition, changes in synaptic plasticity in the ACC are believed to be essential for the development and maintenance of chronic pain.<sup>9</sup> For instance, a brain imaging study found increased ACC neuronal activity in persistent pain conditions,<sup>11</sup> and animal behavior studies employing acute and chronic pain models showed that the development of LTP increases the number of pre- and post-synaptic AMPA and NMDA receptors in the ACC and that drugs that inhibit ACC activity exert analgesic effects.<sup>12</sup> Therefore, these studies suggest that the ACC plays a vital role in processing pain-related information and in behavioral responses to various stimuli including noxious stimuli, inflammation, or nerve injury in humans and animals. In addition, a study utilizing a peripheral amputation model as well as an electrophysiological study reveal that excitatory transmission in the ACC is strengthened after peripheral nerve injury.<sup>13,14</sup> In a rodent model of neuropathic pain, the development of allodynia is associated with synaptic potentiation in the ACC 1–2 wk after nerve injury.<sup>15</sup> This finding suggests that neuropathic pain is associated with mechanisms underlying the development of LTP in the ACC. In addition, nerve damage could induce long-term enhancement of synaptic transmission in the ACC, which would not only increase the release of neurotransmitters from presynaptic terminals but also increase the number of postsynaptic receptors. Preventing, eliminating, or reducing enhancement of excitatory transmission could be applied as a new therapeutic method for suppressing chronic pain. Previous studies show that neurons in the ACC respond to noxious stimuli<sup>16</sup> and that lesioning the ACC significantly reduces acute and neuropathic pain responses.<sup>17</sup> However, inhibition of pain transmission does not prevent chronic pain-related synaptic strengthening, and drugs that suppress synaptic potentiation do not affect acute or physiological pain.<sup>12</sup> Therefore, it is necessary to identify new therapeutic targets for controlling chronic pain by investigating the induction and formation mechanisms of pain-

related LTP. LTP in chronic pain can be classified into early LTP (E-LTP) and late LTP (L-LTP).<sup>18,19</sup> While E-LTP is maintained by the persistent activation of protein kinases which are pre-existing proteins, L-LTP depends primarily on protein synthesis through gene transcription.<sup>20,21</sup> Previous study indicated that the protein synthesis required for the maintenance of L-LTP in vitro can be derived from the translation of pre-existing mRNAs in dendrites and synaptic locations.<sup>22</sup> In particular, L-LTP contributes to long-term changes in the cortical circuit due to synaptic protein synthesis induced by peripheral nerve injury. Thus, the regulation of protein synthesis may be an avenue for controlling LTP, and LTP maintenance and formation could be regulated by modulating mammalian target of rapamycin (mTOR), which is involved in synaptic protein synthesis.

mTOR is a serine-threonine protein kinase that plays a critical role in cell proliferation and differentiation in the nervous system.<sup>23</sup> Activation of mTOR can be controlled through various stimuli (e.g., neurotransmitters, growth factors, cytokines, oxygen, and amino acids).<sup>24</sup> Activation of mTOR affects transcription of mRNA in a variety of physiological and pathologic pain states, including inflammatory and cancer pain,<sup>25-29</sup> by phosphorylating downstream factors such as eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and p70 ribosomal S6 protein kinase (p70S6K) and is reported to be involved in signal transduction through regulation of protein synthesis.<sup>30</sup> mTOR can also regulate cell growth, differentiation, and synaptic plasticity by activating synaptic protein synthesis.<sup>19</sup> Thus, as LTP is maintained through synaptic protein synthesis,<sup>23</sup> the modulation of synaptic protein synthesis through the regulation of mTOR activation may play an important role in LTP changes. Rapamycin, an mTOR inhibitor, has been used as an anticancer and immunosuppressive agent in the clinical treatment and has relatively few side effects compared with other drugs.<sup>29,31</sup> Recent studies suggest that rapamycin, which regulates mTOR and its downstream effectors, could diminish chronic inflammatory, neuropathic, and cancer pain. Studies also report

that mTOR activity is altered in a wide range of pathological states, such as cancer, cardiovascular diseases, and neurodegenerative disorders.<sup>29,32,33</sup> Pain behaviors (e.g., mechanical hypersensitivity) are reduced when rapamycin is intrathecally injected into hyperalgesia or inflammatory pain animal models or locally administrated in neuropathic pain animal models.<sup>25-27</sup> The inhibition of mTOR by treatment with the CCI-779, as confirmed by the decreased expression of downstream signaling molecules in the spinal cord and dorsal roots in a spared nerve injury animal model, exerts a pain-relieving effect.<sup>34</sup> Previous studies report that mRNA translation and local protein synthesis are regulated by inhibiting mTOR activation in several pain models.<sup>35,36</sup> In addition, recent study revealed that rapamycin reduces the expression of downstream signaling molecules and synaptic proteins in the IC.<sup>37</sup> These previous studies strongly suggest that mTOR plays an important role in the modulation of long-term neuronal plasticity by preventing the establishment of LTP. So far, the mTOR pathway has been extensively studied in relation to cancer and described at the spinal cord level in relation to inflammatory and neuropathic pain, but only a few studies have been performed at the brain level. Moreover, there was no studies that have reported pain relief by controlling mTOR in the ACC of neuropathic pain models until now. It is necessary to conduct further studies at the brain level because the mTOR signaling pathway plays an important role in the neuronal plasticity involved in pain processing, such as the development of chronic pain. Therefore, the purpose of the present study was to investigate the association between pain caused by nerve injury and the mTOR signaling pathway in the ACC and to test the pain-relieving effect of rapamycin administration.

## **II. MATERIALS AND METHODS**

### **1. Neuropathic pain model**

#### **A. Animals**

Adult male Sprague-Dawley rats weigh 250–280 g (Harlan, Koatec, Pyeongtaek, Korea) were used in the present study. All animals were maintained under a 12-h light/dark cycle with free access to food and water throughout the study and were allowed to acclimate to the colony room for 7 days after arrival. All experimental protocols were in compliance with the National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee of Yonsei University Health System.

#### **B. Surgical procedure**

A model of neuropathic pain was induced by ligation and cutting of the sciatic nerve branches.<sup>38</sup> Under isoflurane anesthesia, three terminal branches of the left sciatic nerve were exposed by direct incision of the skin and a section of the biceps femoris muscle. The tibial and sural nerves were tightly ligated with 4-0 black silk and cut, and the common peroneal nerve was left intact (nerve-injured; NP group). Surgical procedures for the sham-operated group were identical to those for the NP group except that the nerves were not injured.

## **2. Cannula implantation**

Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and placed in a stereotaxic frame. Stainless steel guide cannulae (28-gauge) were bilaterally implanted into the ACC (AP 1.5 mm from bregma, ML  $\pm$ 0.6 mm from midline, DV 1.5 mm beneath the surface of the skull). The cannulae were attached to bone with stainless steel screws and acrylic cement. Dummy cannulae were inserted into the guide cannulae to avert clogging. Rats were allowed to recover for 7 days after cannula implantation.

## **3. Drug microinjection into the ACC**

Rapamycin (R-5000; LC Laboratories, Woburn, MA, USA) was prepared in 0.06% dimethyl-sulfoxide (DMSO) diluted in saline. Microinjections were performed on POD 7. Rapamycin (0.5  $\mu$ l of 150, 300, and 600 nM per side over 1 min) or an equivalent amount of vehicle solution was microinjected into the ACC bilaterally via the injection cannulae, which were lowered 1 mm deeper into the ACC than the guide cannulae. The microinjection apparatus consisted of a Hamilton syringes (1  $\mu$ l) connected to the injection cannula by the PE-10 tubing. After injection, the injection cannulae were maintained in place for at least 1 min to allow for drug absorption into the brain and to minimize reflux along the track of the cannula.

#### **4. Behavior test**

##### **A. Measuring response withdrawal threshold**

Rats were individually placed in small cages with a metal mesh floor and habituated for 15 min before the test. Mechanical allodynia was measured by assessing thresholds for each hind paw withdrawal from stimulation by an electronic von Frey filament (UGO Basile, Varese, Italy). A single, un-bending filament was vertically applied to the hind paw, and licking or rapid withdrawal of the hind paw was considered as a positive response. Responses were measured seven times in 2–3 min intervals. The mechanical allodynia test was performed before nerve injury and on postoperative days (PODs) 1, 4, 7 and 14 by a researcher blinded to the experimental conditions.

##### **B. Changes of mechanical allodynia after microinjection**

More mechanical allodynia test for confirming the effect of drug administration were also performed before and at 0.5, 1, 2, 4, 8, 12 and 24 hr after rapamycin or vehicle solution microinjection in the ACC on POD 7 by a researcher blinded to microinjection substance.

## 5. Western blot analysis

Two h after microinjection of rapamycin or vehicle solution on POD 7, rats were anesthetized with isoflurane and decapitated for ACC tissue sample collection. The ACC (AP +2.2 to -1.2 from bregma) was dissected on ice using a rat brain matrix (RWD Life Science, Shenzhen, China). Three coronal brain slices (1mm thick) containing the ACC were dissected using a surgical blade and rapidly frozen in liquid nitrogen. For protein extraction, samples were homogenized in lysis buffer (ProPrep; Intron Biotechnology, Pyeongtaek, Korea) containing phosphatase inhibitors (Phosstop; Roche, Mannheim, Germany) and incubated on ice for 2 hr. Samples were then centrifuged at 15,000 rpm for 15 min at 4°C, and supernatants were collected. Total protein concentrations were assessed with a spectrophotometer (Nano Drop ND-1000; NanoDrop Technologies Inc., Wilmington, DE, USA), and equal amounts of protein (30 mg per well) were denatured and loaded on 10% SDS-PAGE (for mTOR, p-mTOR, p70S6K, and p-p70S6K) and 15% SDS-PAGE (for 4E-BP1 and p-4E-BP1) (Bio-Rad, Hercules, CA, USA). Proteins were transferred onto a polyvinylidene difluoride membrane (Merck Millipore, Darmstadt, Germany). Phospho-proteins were immunodetected first followed by the corresponding total protein after the blot was stripped. For enhanced visualization and analysis of 4E-BP1 and p-4E-BP1, transferred proteins were fixed to the membrane by 0.05% glutaraldehyde in TBS-0.05% Tween-20 (TBST) for 15 min at room temperature.<sup>39</sup> Membranes were stained with Ponceau S (Sigma-Aldrich, St. Louis, MO, USA), and staining of the wells was visually compared. Membranes were blocked by incubation in 5% bovine serum albumin in TBST for 1 h at room temperature and incubation overnight at 4°C with primary antibodies diluted in 5% bovine serum albumin in TBST. The following primary antibodies were used: mTOR (no. 2972, 1:1,000; Cell Signaling Technology, Beverly, MA, USA), p-mTOR (Ser 2448, no. 2971,

1:500; Cell Signaling Technology), p70S6K (no. 2708, 1:1,000; Cell Signaling Technology), p-p70S6K (Thr 389, no. 9205, 1:500; Cell Signaling Technology), 4E-BP1 (no. 9644, 1:1,000; Cell Signaling Technology), p-4E-BP1 (Thr37/46, no. 2855, 1:500; Cell Signaling Technology), and  $\beta$ -actin (no. 3700, 1:15,000; Cell Signaling Technology). The next day, blots were washed three times in TBST and incubated with the appropriate anti-rabbit horseradish peroxidase-conjugated secondary antibody (no. 7074, 1:10,000; Cell Signaling Technology). Immunoreactive proteins were visualized by applying a chemiluminescent (ECL) detection reagent (GE Healthcare, Little Chalfont, UK) and observed using an LAS system (LAS 4000, GE Healthcare, Fuji Film Inc., Tokyo, Japan). Phospho-protein and total protein immunoreactivity was scanned and quantified using Multi-gage software (Fuji Film Inc., Tokyo, Japan). Each value was normalized to the respective  $\beta$ -actin band, and optical density was divided by that of the corresponding total protein band to yield a phospho-protein/total protein ratio.

## **6. Histology**

### **A. Immunofluorescence staining**

On POD 7, rats were deeply anesthetized with urethane (1.25 g/kg, i.p.) immediately after mechanical allodynia testing following microinjection of rapamycin or vehicle solution into the ACC and perfused transcardially with normal saline (0.9% NaCl) via the ascending aorta followed by a 4% solution of formaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). Brains were removed, post-fixed in the same paraformaldehyde solution for 4 hr at 4°C, and immersed in a 10% to 30% (w/v) sucrose gradient in phosphate-buffered saline (PBS; pH 7.4) for 24–48 hr at 4°C for cryoprotection. After cryoprotection, brains were embedded in optimal cutting temperature compound (Sakura Finetek USA Inc., Torrance, CA, USA) and cut on a cryostat (Microm HM525; Thermo Scientific,

Waltham, MA, USA) into 20  $\mu\text{m}$ -thick coronal sections. Double immunofluorescence staining for PSD-95/AMPA GluA1 subunits or PSD-95/NMDAR NR2B subunits was performed. Sections containing the ACC were blocked in PBS containing 0.3% Triton X-100 (PBST) and 5% normal donkey serum for 2 h at room temperature. For double immunofluorescence, sections were incubated overnight with a mixture of mouse anti-PSD-95 (1:500, ab2723, Abcam, Cambridge, United Kingdom) and rabbit AMPA GluA1 (1:500, ab31232, Abcam) or rabbit anti-NMDAR2B (1:500, ab65783, Abcam) antibodies in PBST containing 5% normal donkey serum at 4°C. All sections were rinsed with PBST (5 min, three times) after each step. After rinsing, sections were incubated with Cy3-conjugated donkey anti-mouse IgG (H+L) (1:200, 715-165-150, Jackson ImmunoResearch, West Grove, PA, USA) or Alexa Fluor 488-conjugated donkey anti-rabbit IgG (H+L) (1:200, 711-545-152, Jackson ImmunoResearch) secondary antibody for 2 h at room temperature. Sections were mounted with Vectashield containing DAPI to label nuclei (Vector Laboratories, Youngstown, OH, USA). In each experiment, sections from different groups were stained at the same time.

## **B. Image analysis**

High-magnification fluorescent images were taken with a Zeiss LSM 700 confocal microscope (Carl Zeiss, Jena, Germany). Quantitative assessment of PSD-95 and AMPAR or NMDAR immunoreactivity was performed using the ImageJ 1.46r software program (National Institutes of Health, Bethesda, Maryland, USA). In addition, the total number of pixels of the stained area were quantified and expressed as immunodensity. These measurements were performed using two sections randomly selected from the five serial sections of the ACC from each animal. Immunodensities were averaged to obtain a single value for each rat.

## 7. Optical imaging

Before imaging, rats were deeply anesthetized with urethane (1.25 g/kg, i.p.) on POD 7 and given atropine (5 mg/kg, i.p.) to suppress mucus secretion and dexamethasone sulfate (1 mg/kg, i.p.) to reduce swelling of the brain. Rats were then placed in a custom-made stereotaxic frame to stabilize the head during optical imaging. Lidocaine was applied to the skin, and a craniotomy was made that extended AP +6 mm to -2 mm from bregma and ML  $\pm$ 4 mm from midline. The dura over the ACC was carefully removed. To expose the ACC, double closure of the superior sagittal sinus was performed using 4-0 black silk, and the superior sagittal sinus was then cut with microscissors and separated from the cortex. If slight bleeding occurred, it was easily controlled using a saline-moistened cotton compress. This surgical procedure was slightly modified from that described for a rat pinealectomy study and an electrophysiological study.<sup>40,41</sup> The exposed ACC was stained using voltage-sensitive dye (di-2-ANEPEQ, 50 mg/mL in saline; Molecular Probes, Eugene, OR, USA) for 1 h and carefully rinsed with saline. Imaging was performed before and after application of 600 nM rapamycin or vehicle solution directly to the exposed cortex for 30 min. Heart rate was monitored by electrocardiography, and body temperature was maintained at 36°C with a rectal probe and heating pad system (Homeothermic Blanket Control Unit; Harvard Apparatus, Holliston, MA, USA).

A pair of stainless steel electrodes was inserted into the left hind paws where the electronic von Frey filaments had been applied during behavioral testing. Stimulation of the hind paw was done with square pulses (width: 0.1 ms, interstimulus interval: 5 s, intensity: 2.5 mA) using a stimulus isolation unit (World Precision Instruments, Sarasota, FL, USA). Changes in fluorescence after peripheral stimulation were measured using a high-resolution CCD camera (Brainvision Inc., Tokyo, Japan) equipped with a dichroic mirror with a 510–550

nm excitation filter and 590 nm absorption filter. A tungsten halogen lamp (150 W) was used for excitation of fluorescence. The imaging area was  $6.4 \times 4.8 \text{ mm}^2$  and consisted of  $184 \times 124$  pixels. The fluorescence intensity during each trial was detected for approximately 940 ms under an optical microscope (Leica Microsystems Ltd., Heerbrugg, Switzerland) equipped with a  $1\times$  objective and  $1\times$  projection lens. Optical signals were acquired at a rate of 3.7 ms/frame, and averages of 20 trials were recorded by an optical imaging recording system (MiCAM02; Brainvision Inc.). Optical imaging acquisition was triggered by electrocardiogram signals using a stimulus/non-stimulus subtraction method. After optical imaging, rats were euthanized by an overdose of urethane. To normalize the value of each pixel, the ratio of the intensity of fluorescence ( $\Delta F$ ) in each pixel relative to the initial fluorescence intensity ( $F$ ) was expressed as a fractional change ( $\Delta F/F$ ). Amplitudes and excitatory areas of optical signals were measured using a spatial filter ( $9 \times 9$  pixels) to reduce artifacts caused by vibration and brain movements. Using captured images, fractional changes in optical signals (i.e., optical intensity) and areas of activation were quantified. Changes in optical intensity in the ACC were expressed as a percentage of fractional change in fluorescence ( $\% \Delta F/F$ ). Activated areas were analyzed using the activated pixel number divided by the total pixel number in the region of interest (AP +2.2 to +0.2 mm from bregma)  $\times 100$ . Data were collected and analyzed with BV Analyzer software (Brainvision Inc.).

## **8. Statistical analysis**


Statistical analyses were performed using SPSS 20.0 software (IBM Corporation, Armonk, NY, USA). Behavioral data were analyzed by two-way repeated measures analysis of variance (ANOVA) followed by Bonferroni's tests for post-hoc comparisons. Western blotting and immunohistochemistry data were analyzed by one-way ANOVA followed by Tukey's tests for multiple comparisons. Optical imaging data were analyzed by unpaired t-tests. All values are expressed as mean  $\pm$  standard error of the mean (SEM). P-values less than 0.05 were considered statistically significant.

### **III. RESULTS**


#### **1. Development of mechanical allodynia induced by nerve injury**

To confirm the development of mechanical allodynia, hind-paw withdrawal threshold was examined in our neuropathic pain animal model using the electronic von Frey 1, 4, 7, and 14 days after neuropathic pain surgery (Figure 1 A). From POD 1 to POD 14, withdrawal threshold was significantly decreased in the NP group (n = 6) compared with the control (Sham) group (n = 6;  $P < 0.001$ ; two-way repeated measures ANOVA followed by Bonferroni tests, Figure 1B). However, there was no significant difference between groups before surgery.

A



B




**Figure 1. Electronic von Frey test and development of mechanical allodynia.**

(A) Illustration of electronic von Frey test for assessing mechanical withdrawal threshold. Rats were individually placed on a metal mesh floor in small plastic cages. A filament was vertically applied to a hind paw, and force was measured until paw withdrawal occurred and was displayed by the device. (B) Development of mechanical allodynia in nerve-injured (NP) and sham-injured (Sham) rats. After nerve injury, significantly higher mechanical withdrawal thresholds were observed in the NP group on POD 1, 4, 7, and 14 compared with those in the Sham group. Data are presented as mean  $\pm$  standard error of mean (SEM). \*\*P < 0.01 vs. Sham, two-way repeated measures analysis of variance (ANOVA) followed by Bonferroni tests.


## 2. Nerve injury activates mTOR signaling in the ACC


Based on behavioral results, it was assumed that mTOR signaling pathway in the ACC would be altered during the development of chronic pain after nerve injury. Western blot analysis was conducted to confirm this hypothesis. Total and phosphorylated protein levels of mTOR and its downstream effectors, p70S6K and 4E-BP1, in the ACC were measured 1, 4, 7, and 14 days after nerve injury (NP\_1, NP\_4, NP\_7, and NP\_14) as well as in normal and sham injury groups. The results indicate that phosphorylated mTOR (p-mTOR) was significantly up-regulated in the NP\_7 group compared with the normal group ( $n = 6$ ;  $P < 0.01$ , one-way ANOVA followed by Tukey's multiple comparison tests, Figure 2A). Furthermore, levels of p-p70S6K and p-4E-BP1 were significantly elevated in NP\_7 group compared with the normal group ( $n = 6$ ;  $P < 0.05$ , one-way ANOVA followed by Tukey's multiple comparison tests, Figure 2B and C), whereas there were no group differences in the total forms of these proteins ( $P > 0.05$ , one-way ANOVA followed by Tukey's multiple comparison tests). Thus, activation of mTOR and its downstream effectors in the ACC gradually increased after nerve injury and peaked on POD 7. However, expression of p-mTOR, p-p70S6K, and p-4E-BP1 declined slightly between POD 7 and POD 14.

# A



# B






**Figure 2. Activation of mTOR and its Downstream Effectors in the ACC after Nerve Injury.** (A-C) Expression levels of p-mTOR, p-p70S6K, and p-4E-BP1 after nerve injury. Levels of p-mTOR, p-p70S6K, and p-4E-BP1 gradually increased after nerve injury as shown by western blot analysis. Seven days after nerve injury (NP\_7), p-mTOR, p-p70S6K, and p-4E-BP1 expression were significantly up-regulated compared with the Normal group, but all phospho-protein levels declined 14 days after nerve injury (NP\_14) as compared with the NP\_7 group. Total protein levels in all groups did not change over time. Data are presented as mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.001$  vs. Normal, one-way ANOVA followed by Tukey's multiple comparison tests.


### **3. Microinjection of rapamycin into the ACC diminishes mechanical allodynia after nerve injury**

After the establishment of mechanical allodynia, rapamycin (150, 300, or 600 nM;  $n = 8$ ) or vehicle ( $n = 8$ ) was injected into the ACC (Figure 3A). Mechanical sensitivity was examined 0.5, 1, 2, 4, 8, 12, and 24 hr after injection. All rapamycin-injected groups showed a reduced response to mechanical stimulation as measured in the von Frey test (Figure 3B). The response to mechanical stimulation in the 150 nM rapamycin group significantly increased from 0.5 hr to 2 hr (0.5 hr and 1 hr  $P < 0.01$ , 2 hr  $P < 0.05$  vs. vehicle group, two-way repeated measures ANOVA followed by Bonferroni tests), and the analgesic effect of 300 nM rapamycin persisted from 0.5 hr to 4 hr (0.5 hr to 4 hr  $P < 0.01$  vs. vehicle group, two-way repeated measures ANOVA followed by Bonferroni tests). However, 600 nM rapamycin was the most effective dose (0.5 hr to 8 hr  $P < 0.01$ , 12 hr  $P < 0.05$  vs. vehicle group, two-way repeated measures ANOVA followed by Bonferroni tests). No change in withdrawal threshold to mechanical stimuli was observed in the vehicle group during the 24 h after microinjection ( $P > 0.05$ , two-way repeated measures ANOVA).

**A**



**B**




**Figure 3. Microinjection of rapamycin into the ACC suppresses activation of mTOR and its downstream effectors after nerve injury.** (A) Stereotaxic location of rapamycin microinjection into the ACC. Red dots point at microinjection sites and Cg1 indicates cingulate cortex, area 1 in the rat brain atlas. Stainless steel guide cannulae for drug microinjection were bilaterally implanted into the ACC. (B) Changes in paw withdrawal threshold to mechanical stimulation after microinjection of rapamycin or vehicle on POD 7. Significant differences in withdrawal threshold between 150 nM rapamycin and Vehicle groups were observed between 0.5 hr and 2 hr after microinjection. Withdrawal thresholds in the 300 nM rapamycin group were significantly elevated between 0.5 hr and 4 hr after microinjection. The most pronounced changes in withdrawal threshold were observed in the 600 nM rapamycin group, with significant changes observed between 0.5 hr and 8 hr after microinjection. Data are presented as mean  $\pm$  SEM. \*P < 0.05, \*\*P < 0.01 vs. Vehicle, two-way repeated measures ANOVA followed by Bonferroni tests.


#### **4. Microinjection of rapamycin into the ACC blocks activation of mTOR and its downstream effectors in the ACC after nerve injury**


Changes in the mTOR signaling pathway after rapamycin injection were confirmed by western blot analysis. As the highest paw withdrawal threshold was reached 2 hr after 600 nM rapamycin injection and persisted to 4 hr. To assess the mTOR activity, tissues were collected 2 hr after rapamycin or vehicle microinjection on POD 7 and measured the expression of mTOR and its downstream effectors. The levels of p-mTOR, p-p70S6K, and p-4E-BP1 in the Vehicle group were significantly higher than those in the Sham group ( $P < 0.05$ , one-way ANOVA followed by Tukey's multiple comparison tests, Figure 4A-C), and the rapamycin groups tended to exhibit a gradual decrease in phospho-protein levels in a dose-dependent manner. In particular, the level of p-mTOR in the 600 nM rapamycin group was significantly lower than that in the Vehicle group ( $P < 0.01$ , one-way ANOVA followed by Tukey's multiple comparison test, Figure 4A). In addition, p-p70S6K and p-4E-BP1 expression was significantly lower than that in the Vehicle group ( $P < 0.05$ , one-way ANOVA followed by Tukey's multiple comparison tests, Figure 4B and C), but there were no changes in total protein levels ( $P > 0.05$ , one-way ANOVA).

**A**



**B**








**Figure 4. Microinjection of rapamycin into the ACC suppresses activation of mTOR and its downstream effectors after nerve injury.** (A-C) Expression of p-mTOR, p-p70S6K, and p-4E-BP1 after microinjection of rapamycin. Levels of p-mTOR, p-p70S6K, and p-4E-BP1 were significantly increased in the Vehicle group compared with the Sham group and significantly decreased in all rapamycin groups (Rapa) compared with the Vehicle group in a dose-dependent manner. Levels of p-mTOR, p-p70S6K, and p-4E-BP1 were most prominently reduced in the 600 nM rapamycin group compared with the Vehicle group. Total protein levels were similar among groups. Data are presented as mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$  vs. Sham, # $P < 0.05$  vs. Vehicle, one-way ANOVA followed by Tukey's multiple comparison tests.

## **5. Inhibition of mTOR suppresses synaptic protein expression in the ACC after nerve injury**


To determine the effect of rapamycin-induced inhibition of mTOR signaling on synaptic protein synthesis, immunofluorescence staining was performed. The results showed changes in the co-localization relative intensity of PSD-95 and glutamate receptors (AMPA GluA1 subunit or NMDAR NR2B subunit) in the ACC 2 h after rapamycin or vehicle microinjection on POD 7. Figure 5A shows location of the ACC used for staining analysis. Cg1 indicates cingulate cortex, area 1 in the rat brain atlas. AMPAR-PSD-95 and NMDAR-PSD-95 co-localization were markedly increased in ACC layer II/III after peripheral nerve injury (Figure 5B and C). Moreover, rapamycin injection resulted in a dose-dependent reduction in the percentage of co-localization relative intensity of PSD-95 and glutamate receptors in the ACC compared with that in the Vehicle group. Specifically, AMPAR-PSD-95 co-localization was significantly lower in the 600 nM group than in the Vehicle group ( $P < 0.01$ , one-way ANOVA followed by Tukey's multiple comparison test, Figure 5D), and NMDAR-PSD-95 co-localization was significantly lower in the 300 nM and 600 nM groups than in the Vehicle group ( $P < 0.01$ , one-way ANOVA followed by Tukey's multiple comparison tests, Figure 5E).




C



D





**Figure 5. Synaptic protein expression after inhibition of mTOR signaling in the ACC.** (A) Location of the ACC used for staining analysis. Cg1 indicates cingulate cortex, area 1 in the rat brain atlas and red square indicates location for staining analysis. (B) Different sets of ACC tissue treated with rapamycin (Rapa) or Vehicle on POD 7 were subjected to immunofluorescence staining with anti-PSD-95 (red), anti-GluA1 (green) or anti-NR2B (green), and DAPI (blue). Representative immunofluorescence staining of PSD-95, AMPA receptor GluA1 subunit, and nuclei (DAPI). Scale bar = 10  $\mu$ m. (C) Percentage of co-localization relative intensity of PSD-95 and AMPA GluA1 receptor subunit expression. The percentage was significantly higher in the Vehicle group than in the Sham group, and the percentages in the Rapa groups declined in a dose-dependent manner. The 600 nM group showed a significant decrease compared with the Vehicle group. (D) Representative immunofluorescence staining of PSD-95, NMDA receptor NR2B subunit, and nuclei (DAPI). Scale bar = 10  $\mu$ m. (E) Percentage of co-localization relative intensity of PSD-95 and NMDA NR2B receptor subunit expression. The percentage was significantly higher in the Vehicle group than in


the Sham group, and the percentages in the Rapa groups declined in a dose-dependent manner. The 300 nM and 600 nM groups showed significantly decreases compared with the Vehicle group. Data are presented as mean  $\pm$  SEM. \*\*P < 0.01 vs. Sham, ##P < 0.01 vs. Vehicle, one-way ANOVA followed by Tukey's multiple comparison tests.

## **6. Inhibition of mTOR reduces excitability in the ACC induced by peripheral stimulation**


Optical imaging using voltage-sensitive dye is a convenient approach to measuring cortical activity after peripheral stimulation. In the present study, the ACC of nerve-injured rats to detect optical signal changes after electrical stimulation of the hind paw was imaged. To investigate differences in spatiotemporal patterns in the ACC of sham (Sham) versus nerve-injured (NP) rats, dorsal view of the exposed cortex was illustrated (Figure 6A) and obtained representative optical images after electrical stimulation of the contralateral hind paw (Figure 6B). Color-coded images in the left side of Figure 6B are optical signals of the activated ACC induced by peripheral stimulation based on fractional changes in reflected light intensity ( $\% \Delta F/F$ ), and wave forms in the right side of Figure 6B show optical responses at specific points in the ACC. Whereas the ACC of NP rats showed optical responses, little change in optical signals and wave forms in the ACC were found after 2.5 mA electrical peripheral stimulation in Sham rats.

Figure 6C and D show representative optical images before and after vehicle treatment or 600 nM rapamycin treatment, respectively, following 2.5 mA electrical peripheral stimulation in nerve-injured rats. As found a maximal pain-relieving effect of 600 nM rapamycin injection, 600 nM rapamycin was used to validate neural activity in the ACC. After rapamycin treatment, neuronal activity in the ACC was strikingly reduced compared with that before treatment. Peak amplitudes induced by peripheral electrical stimulation was reduced after rapamycin treatment compared with before rapamycin treatment ( $n = 6$ ,  $P < 0.01$ , unpaired t-test, Figure 6E). Also, the area of activation was reduced after rapamycin treatment compared with before rapamycin treatment ( $n = 6$ ,  $P < 0.01$ , unpaired t-test, Figure 6F). By contrast, peak amplitude and activated area were


not significantly different before and after vehicle treatment ( $P > 0.05$ , unpaired t-tests).




**B**




C



D





**Figure 6. Changes in optical signals in the ACC.** (A) Dorsal view of the exposed cortex and representative image. The inner area of the dotted red lines indicates the ACC region. (B) Representative optical images and signals in the ACC from sham-injured (Sham, upper) and nerve-injured (NP, lower) rats. Red arrows indicate time point of electrical stimulation. NP rats showed a larger activated area in the ACC and increased peak amplitude after peripheral stimulation (2.5 mA) compared with Sham rats. Scale bar = 1 mm. (C-D) Optical signals from NP rats before and after vehicle or 600 nM rapamycin treatment. Blue lines mean before treatment and red lines mean after treatment in the optical signals. (E-F) Peak amplitudes and activated areas before and after vehicle or rapamycin treatment following peripheral electrical stimulation (2.5 mA). The peak amplitude and activated area induced by peripheral electrical stimulation after rapamycin treatment were significantly lower than those before rapamycin treatment. However, they were similar before and after vehicle treatment. Data are presented as mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$ , unpaired t-tests.

#### IV. DISCUSSION

Changes in synaptic plasticity in many areas of the central nervous system are involved in pain processing and chronic pain, including the spinal cord, cortical areas, and subcortical areas.<sup>10,12</sup> Previous studies show that changes of neural plasticity in the ACC are associated with persistent pain and fear memory in a mouse model.<sup>42</sup> ACC neurons respond to nociceptive and non-nociceptive mechanical or thermal somatosensory stimuli as well as emotional aspects of pain.<sup>16,43,44</sup> In particular, nociceptive information is projected to the ACC from other pain-related regions, such as the medial thalamus, amygdala, and other pain-related area of the cortex.<sup>45</sup>

Recently, mTOR has been found to control cancer, inflammatory, and neuropathic pain.<sup>27,29,34,46</sup> These studies provide evidence that mTOR plays an important role in pain management but have mainly focused on mechanisms at the spinal level. The present study validated the role of mTOR signaling at the brain level by examining mechanical hyperalgesia and changes in the expression of activated mTOR (p-mTOR) and its downstream effectors (p-p70S6K and p-4E-BP1) in the ACC after nerve injury in an animal model of neuropathic pain. These results suggest that the development of neuropathic pain induced by peripheral nerve injury is associated with increased activity of mTOR and its downstream effectors in the ACC. Previous studies report increased activity of mTOR and its downstream effectors in the spinal cord dorsal horn in the chronic constriction injury model,<sup>47</sup> the rostral ventromedial medulla in the spared nerve injury model,<sup>48</sup> and the IC in the nerve-injured model.<sup>37</sup> Also, another study reports increased expression of p-mTOR and p-p70S6K in the ACC of a formalin-induced inflammatory animal model.<sup>49</sup> Together with previous studies, these results demonstrate that the mTOR-dependent signaling pathway in the ACC is involved in the development of chronic pain. In addition, observations in this

study might demonstrate that the mTOR signaling is less affected after the development of chronic pain as activation of mTOR and its downstream effectors was reduced 14 days compared with 7 days after nerve injury.

Previous electrophysiological studies show that rapamycin, an mTOR inhibitor, inhibits L-LTP in the hippocampus when delivered during LTP induction but not after LTP formation.<sup>18,50</sup> Also, intrathecal injection of rapamycin reduces mechanical hyperalgesia behaviors and decreases phosphorylation of mTOR and its downstream effectors in the spinal cord dorsal horn in chronic constriction injury and spinal cord injury animal models.<sup>25,47</sup> These results indicate that neuropathic pain could be regulated by rapamycin. In the present study, mechanical allodynia was significantly reduced after microinjection of rapamycin into the ACC, and levels of phosphorylation of mTOR, p70S6K, and 4E-BP1 were significantly decreased in a dose-dependent manner. In particular, 600 nM rapamycin was the most effective dosage for reducing mechanical allodynia and phosphorylation of mTOR, p70S6K, and 4E-BP1. Thus, these results suggest that rapamycin reduces pain-related behaviors by inhibiting the activation of mTOR.

mTOR regulates synaptic protein transcription via many factors.<sup>51</sup> Activation of mTOR regulates the phosphorylation of downstream effectors such as p70S6K and 4E-BP1, which in turn regulate mRNA translation and protein synthesis<sup>30,52</sup> and thereby affect protein translation.<sup>25</sup> Local protein synthesis in axons and dendrites contributes to regulating long-lasting synaptic plasticity, neurite development, and response to nerve injury.<sup>53,54</sup> It is well known that mTOR regulates local transcription of mRNA through phosphorylation of p70S6K and 4E-BP1.<sup>50</sup> Phosphorylation of p70S6K mediates translation initiation and polypeptide extension, whereas phosphorylation of 4E-BP1 reduces cap-dependent transcription by inhibiting eukaryotic initiation factor 4E (eIF4E).<sup>52</sup> Activation of mTOR signaling induces dendritic protein synthesis, including the synthesis of postsynaptic glutamate receptors and postsynaptic density proteins

necessary for maintaining long-lasting forms of synaptic plasticity, especially L-LTP.<sup>52,55</sup> In addition, activation of postsynaptic receptors affects the development of chronic hyperalgesia to noxious stimuli.<sup>56</sup> Post-synaptic density (PSD), which binds to postsynaptic receptors and adhesion molecules, is maintained by an abundant set of scaffold proteins and has a role in mediating activation of synaptic receptors for biochemical signaling events in post-synaptic neurons.<sup>57</sup> In particular, the interaction between the NMDA receptor NR2B subunit and PSD-95 plays an important role in synaptic plasticity in the central nervous system underlying the development of neuropathic pain after peripheral nerve injury.<sup>14</sup> The AMPA receptor GluA1 subunit also contributes to pain-related LTP expression in the ACC.<sup>58</sup> Thus, it is possible that the mTOR pathway induces long-term changes in synaptic efficacy by facilitating interaction of glutamate receptors with PSD proteins, leading to the long-lasting synaptic plasticity associated with chronic pain.

Here, it provides strong evidence that mTOR contributes to neuropathic pain induced by peripheral nerve injury by increasing the excitability of pyramidal neuron in the ACC. Immunofluorescence staining showed that the expression of PSD-95 was increased at apical dendrites of ACC pyramidal neurons after nerve injury and confirmed increased interactions between PSD-95 and glutamate receptors (AMPA GluA1 and NMDAR NR2B subunits). In addition, rapamycin administration into the ACC decreased the expression of and interaction between these synaptic proteins. These results demonstrate that rapamycin suppresses the activity of mTOR and its downstream effectors, thereby decreasing translation and synthesis of mTOR-mediated synaptic proteins. Because both the ACC and primary somatosensory cortex, which are located in the pain ascending pathway, receive nociceptive inputs from the medial thalamus, the increased activity of pyramidal cells in both areas reflects their participation in a cerebral cortical circuit involved in chronic pain. In fact, electrophysiological studies show the

activation of many pyramidal neurons of ACC layer II/III after nerve injury,<sup>59,60</sup> and some studies show that inhibiting the hyperactivity or plasticity of pyramidal neurons in the ACC lessens the development of chronic pain.<sup>59,61</sup> Combining current results with those of previous studies, it could speculate that rapamycin modulates the interaction between GluA1-PSD-95 and NR2B-PSD-95 by regulating the mTOR signaling pathway that controls synaptic plasticity in the ACC. In other words, mTOR signaling in the ACC is an important component in neuropathic pain induced by nerve damage. Synaptic protein synthesis regulation through inhibition of mTOR activity in the ACC leads to changes of synaptic plasticity. Local protein synthesis, in particular, induces synaptogenesis to enable more sensitive signal transduction.<sup>62</sup> Previous study has shown that modulating mTOR activity with ketamine could affect synaptogenesis.<sup>63</sup> These suggest that pain relieving effect of mTOR pathway inhibition may affect synaptogenesis as well as synaptic strength.

Optical imaging using voltage-sensitive dye was performed as an additional means to verify neuronal activation of the ACC in neuropathic pain and to demonstrate changes in neuronal activity after rapamycin treatment. This electrophysiological technique allows the recording of membrane potential changes to provide visual confirmation of the activity of the neuronal population.<sup>64</sup> Electrical stimuli were delivered to hind paws to observe changes in nerve activity after rapamycin treatment in the ACC of an animal nerve injury model. The results indicate that the ACC of neuropathic rats was extensively activated in response to peripheral electrical stimulation, and this ACC activation was diminished by rapamycin. In other words, excitability in the ACC after nerve injury decreased after treatment with an mTOR inhibitor. These results are consistent with previous studies confirming that neuronal activities were reduced by inhibiting protein synthesis in the L-LTP phase.<sup>22,65,66</sup> In addition, similar results were reported using rapamycin in the IC, which is also involved in pain

processing.<sup>37</sup> These findings, together with those of previous studies, indicate that rapamycin could reduce the response to peripheral stimulation before the development of LTP.

## V. CONCLUSION

The purpose of this study was to validate the efficacy of inhibiting mTOR activation in the ACC in relieving neuropathic pain caused by nerve injury. Consistent with previous studies, these findings suggest that protein synthesis, which maintains a chronic pain state, is suppressed by inhibiting the activity of mTOR prior to LTP development. However, the effect of pain relief did not persist more than 24 hr after rapamycin microinjection; therefore, future studies investigating the maintenance of this effect are needed. In conclusion, the present study suggests that the mTOR pathway in the ACC is an important avenue for controlling neuropathic pain produced by peripheral nerve damage and provides evidence for a vital role of synaptic plasticity in the ACC in the processing of pain.

## REFERENCE

1. Zhuo M. Neuronal mechanism for neuropathic pain. *Mol Pain* 2007;3:14.
2. Hagen EM, Rekan T. Management of Neuropathic Pain Associated with Spinal Cord Injury. *Pain Ther* 2015;4:51-65.
3. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nat Med* 2004;10:685-92.
4. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet* 1999;353:1959-64.
5. Xu B, Descalzi G, Ye HR, Zhuo M, Wang YW. Translational investigation and treatment of neuropathic pain. *Mol Pain* 2012;8:15.
6. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. *Eur J Pain* 2005;9:463-84.
7. Johansen JP, Fields HL, Manning BH. The affective component of pain in rodents: direct evidence for a contribution of the anterior cingulate cortex. *Proc Natl Acad Sci U S A* 2001;98:8077-82.
8. Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ. The integration of negative affect, pain and cognitive control in the cingulate cortex. *Nat Rev Neurosci* 2011;12:154-67.
9. Zhuo M. Long-term potentiation in the anterior cingulate cortex and chronic pain. *Philos Trans R Soc Lond B Biol Sci* 2014;369:20130146.
10. Sandkuhler J. Understanding LTP in pain pathways. *Mol Pain* 2007;3:9.
11. Yuan W, Dan L, Netra R, Shaohui M, Chenwang J, Ming Z. A pharmacofMRI study on pain networks induced by electrical stimulation after sumatriptan injection. *Exp Brain Res* 2013;226:15-24.
12. Zhuo M. Cortical excitation and chronic pain. *Trends Neurosci* 2008;31:199-207.
13. Wei F, Zhuo M. Potentiation of sensory responses in the anterior cingulate cortex following digit amputation in the anaesthetised rat. *J Physiol* 2001;532:823-33.
14. Xu H, Wu LJ, Wang H, Zhang X, Vadakkan KI, Kim SS, et al. Presynaptic and postsynaptic amplifications of neuropathic pain in the anterior cingulate cortex. *J Neurosci* 2008;28:7445-53.

15. Koga K, Descalzi G, Chen T, Ko HG, Lu J, Li S, et al. Coexistence of two forms of LTP in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain. *Neuron* 2015;85:377-89.
16. Hutchison WD, Davis KD, Lozano AM, Tasker RR, Dostrovsky JO. Pain-related neurons in the human cingulate cortex. *Nat Neurosci* 1999;2:403-5.
17. Qu C, King T, Okun A, Lai J, Fields HL, Porreca F. Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. *Pain* 2011;152:1641-8.
18. Cammalleri M, Lutjens R, Berton F, King AR, Simpson C, Francesconi W, et al. Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. *Proc Natl Acad Sci U S A* 2003;100:14368-73.
19. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. *Neuron* 2009;61:10-26.
20. Vickers CA, Wyllie DJ. Late-phase, protein synthesis-dependent long-term potentiation in hippocampal CA1 pyramidal neurones with destabilized microtubule networks. *Br J Pharmacol* 2007;151:1071-7.
21. Huang EP. Synaptic plasticity: going through phases with LTP. *Curr Biol* 1998;8:R350-2.
22. Tsokas P, Grace EA, Chan P, Ma T, Sealfon SC, Iyengar R, et al. Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. *J Neurosci* 2005;25:5833-43.
23. Bockaert J, Marin P. mTOR in Brain Physiology and Pathologies. *Physiol Rev* 2015;95:1157-87.
24. Takei N, Inamura N, Kawamura M, Namba H, Hara K, Yonezawa K, et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. *J Neurosci* 2004;24:9760-9.
25. Wang X, Li X, Huang B, Ma S. Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury. *Transl Neurosci* 2016;7:50-5.

26. Asante CO, Wallace VC, Dickenson AH. Formalin-induced behavioural hypersensitivity and neuronal hyperexcitability are mediated by rapid protein synthesis at the spinal level. *Mol Pain* 2009;5:27.
27. Norsted Gregory E, Codeluppi S, Gregory JA, Steinauer J, Svensson CI. Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. *Neuroscience* 2010;169:1392-402.
28. Lisi L, Aceto P, Navarra P, Dello Russo C. mTOR kinase: a possible pharmacological target in the management of chronic pain. *Biomed Res Int* 2015;2015:394257.
29. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. *Cell Cycle* 2009;8:3831-7.
30. Hay N, Sonenberg N. Upstream and downstream of mTOR. *Genes Dev* 2004;18:1926-45.
31. Alamo JM, Barrera L, Casado MD, Bernal C, Marin LM, Suarez G, et al. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. *Transplant Proc* 2009;41:2181-3.
32. Ma T, Hoeffler CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. *PLoS One* 2010;5.
33. Sciarretta S, Volpe M, Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. *Circ Res* 2014;114:549-64.
34. Obara I, Tochiki KK, Geranton SM, Carr FB, Lumb BM, Liu Q, et al. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. *Pain* 2011;152:2582-95.
35. Antion MD, Merhav M, Hoeffler CA, Reis G, Kozma SC, Thomas G, et al. Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. *Learn Mem* 2008;15:29-38.
36. Banko JL, Poulin F, Hou L, DeMaria CT, Sonenberg N, Klann E. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. *J Neurosci* 2005;25:9581-90.
37. Kwon M, Han J, Kim UJ, Cha M, Um SW, Bai SJ, et al. Inhibition of Mammalian

- Target of Rapamycin (mTOR) Signaling in the Insular Cortex Alleviates Neuropathic Pain after Peripheral Nerve Injury. *Front Mol Neurosci* 2017;10:79.
38. Lee BH, Won R, Baik EJ, Lee SH, Moon CH. An animal model of neuropathic pain employing injury to the sciatic nerve branches. *Neuroreport* 2000;11:657-61.
39. Wang X, Proud CG. Methods for studying signal-dependent regulation of translation factor activity. *Methods Enzymol* 2007;431:113-42.
40. Lee BH, Lamour Y, Bassant MH. Iontophoretic study of medial septal neurons in the unanesthetized rat. *Neurosci Lett* 1991;128:29-32.
41. Maganhin CC, Simoes RS, Fuchs LF, Oliveira-Filho RM, Simoes Mde J, Evencio Neto J, et al. Rat pinealectomy: a modified direct visual approach. *Acta Cir Bras* 2009;24:321-4.
42. Zhao MG, Ko SW, Wu LJ, Toyoda H, Xu H, Quan J, et al. Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. *J Neurosci* 2006;26:8923-30.
43. Iwata K, Kamo H, Ogawa A, Tsuboi Y, Noma N, Mitsuhashi Y, et al. Anterior cingulate cortical neuronal activity during perception of noxious thermal stimuli in monkeys. *J Neurophysiol* 2005;94:1980-91.
44. Koga K, Li X, Chen T, Steenland HW, Descalzi G, Zhuo M. In vivo whole-cell patch-clamp recording of sensory synaptic responses of cingulate pyramidal neurons to noxious mechanical stimuli in adult mice. *Mol Pain* 2010;6:62.
45. Bliss TV, Collingridge GL, Kaang BK, Zhuo M. Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. *Nat Rev Neurosci* 2016;17:485-96.
46. Jaworski J, Sheng M. The growing role of mTOR in neuronal development and plasticity. *Mol Neurobiol* 2006;34:205-19.
47. Hoeffler CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. *Trends Neurosci* 2010;33:67-75.
48. Zhang W, Sun XF, Bo JH, Zhang J, Liu XJ, Wu LP, et al. Activation of mTOR in the spinal cord is required for pain hypersensitivity induced by chronic constriction injury in mice. *Pharmacol Biochem Behav* 2013;111:64-70.
49. Wang J, Feng DY, Li ZH, Feng B, Zhang H, Zhang T, et al. Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla

- Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in Rat. *Neural Plast* 2015;2015:394820.
50. Lu B, Jiang J, Sun J, Xiao C, Meng B, Zheng J, et al. Inhibition of mammalian target of rapamycin activation in the rostral anterior cingulate cortex attenuates pain-related aversion in rats. *Behav Brain Res* 2016;310:51-8.
  51. Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, et al. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. *J Neurosci* 2009;29:15017-27.
  52. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol* 2009;10:307-18.
  53. Sutton MA, Schuman EM. Dendritic protein synthesis, synaptic plasticity, and memory. *Cell* 2006;127:49-58.
  54. Wang DO, Martin KC, Zukin RS. Spatially restricting gene expression by local translation at synapses. *Trends Neurosci* 2010;33:173-82.
  55. Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. *Physiology (Bethesda)* 2006;21:362-9.
  56. Lyu D, Yu W, Tang N, Wang R, Zhao Z, Xie F, et al. The mTOR signaling pathway regulates pain-related synaptic plasticity in rat entorhinal-hippocampal pathways. *Mol Pain* 2013;9:64.
  57. Sheng M, Kim E. The postsynaptic organization of synapses. *Cold Spring Harb Perspect Biol* 2011;3.
  58. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. *Science* 2000;287:2262-7.
  59. Li XY, Ko HG, Chen T, Descalzi G, Koga K, Wang H, et al. Alleviating neuropathic pain hypersensitivity by inhibiting PKMzeta in the anterior cingulate cortex. *Science* 2010;330:1400-4.
  60. Chen Z, Shen X, Huang, Wu H, Zhang M. Membrane potential synchrony of neurons in anterior cingulate cortex plays a pivotal role in generation of neuropathic pain. *Sci Rep* 2018;8:1691.
  61. Kang SJ, Kwak C, Lee J, Sim SE, Shim J, Choi T, et al. Bidirectional modulation

- of hyperalgesia via the specific control of excitatory and inhibitory neuronal activity in the ACC. *Mol Brain* 2015;8:81.
62. Shen K, Cowan CW. Guidance molecules in synapse formation and plasticity. *Cold Spring Harb Perspect Biol* 2010;2:a001842.
  63. Dwyer JM, Duman RS. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. *Biol Psychiatry* 2013;73:1189-98.
  64. An S, Yang JW, Sun H, Kilb W, Luhmann HJ. Long-term potentiation in the neonatal rat barrel cortex in vivo. *J Neurosci* 2012;32:9511-6.
  65. Fonseca R, Nagerl UV, Bonhoeffer T. Neuronal activity determines the protein synthesis dependence of long-term potentiation. *Nat Neurosci* 2006;9:478-80.
  66. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. *Proc Natl Acad Sci U S A* 2002;99:467-72.

## ABSTRACT (IN KOREAN)

신경병증성 통증 모델의 Anterior Cingulate Cortex 에 작용하는  
mTOR 억제제의 통증 완화 효과

<지도교수 이 배 환>

연세대학교 대학원 의과학과

엄 선 우

통증과 관련된 많은 뇌 영역 중에서 전대상피질(anterior cingulate cortex, ACC)은 통증 지각과 관련된 주된 영역으로 알려져 있으며, 다양한 연구에서 ACC는 통증과 관련된 감정적인 요인을 처리하는데 관여한다고 보고되고 있다. 말초 신경 손상 이후 비정상적인 감각 신호 전달에 의해 유발 되는 장기간 증강(long-term potentiation, LTP) 은 중추신경계의 만성 통증의 주요 특징 중 하나로, LTP로 유도된 흥분성 전달 강화를 예방하거나 제거 혹은 감소시키는 것이 만성통증을 억제하는 새로운 치료방법으로 적용될 수 있을 것이다. 따라서 통증 관련 LTP의 유도 및 발현 메커니즘에 대한 연구를 통해 만성 통증을 조절하기 위한 새로운 치료 표적을 밝혀내는 것이 필요하다. Mammalian target of rapamycin (mTOR) 은 세린-트레오닌 단백질 인산화 효소로, mTOR의 활성화는 eukaryotic initiation factor 4E binding protein 1 (4E-BP1) 및 p70 ribosomal S6 protein kinase(p70S6K)와 같은 하위 인자들을 인산화 시킴으로써 단백질 합성에 중요한 역할을 하는 것으로 잘 알려져 있다. 현재까지는 면역억제제 또는 항암제로 많이 사용되고 있으며, 다른 약물들에 비해 부작용이 적은 것으로 보고 되고 있다. 또한 이 mTOR 신호 전달 경로가 통증 처리와 관련되어 있다는 견해를 뒷받침하는 많은 증거가 있어 mTOR와 관련된 신호 전달 과정이 만성 통증의 발달 과정에서

발생하는 신경가소성 변화에 중요한 역할을 하고 있다는 것을 알 수 있다. 그러나 현재까지의 연구들은 주로 척추 수준에서 진행되어 대뇌 수준에서의 mTOR 신호 전달 경로와 신경병증성 통증에 대한 연구가 필요하다. 따라서 본 연구는 말초 신경이 손상된 수컷 Sprague-Dawley 흰쥐를 이용하여, ACC에서 신경 손상 이후 통증과 이에 관여하는 mTOR 신호 전달과의 연관성 및 상호 작용에 대해 알아보고, mTOR 억제제인 라파마이신 투여가 이러한 신경병증성 통증 및 만성통증을 일으킬 수 있는 LTP를 조절함으로써 나타내는 통증 완화 효과에 대해 알아보고자 하였다. 기계적 이질통을 확인하기 위해 행동검사를 시행하였고, 광영상 기법을 통해 말초 자극으로 인한 ACC 신경 반응을 확인하였다. 라파마이신에 의한 mTOR억제는 기계적 이질통, ACC에서의 신호 전달을 감소시켰으며, 흥분성 신호전달에 관여하는 시냅스 단백질인 PSD-95와 NMDA/AMPA 수용체의 발현을 감소시킴으로써 신경병증성 통증 유발로 인한 시냅스 가소성을 감소시켰다. 광영상 기법 분석은 라파마이신 치료가 ACC에서 말초 전기 자극에 의해 신경 세포 활동을 유의하게 감소시킨다는 것을 보여준다. 이러한 결과는 라파마이신이 ACC에서 mTOR 활성을 억제함으로써 말초 신경 손상이 만성 통증으로 발달하기 전에 신경병증성 통증의 치료 및 관리를 위한 새로운 경로를 제공할 수 있음을 보여줄 수 있음을 시사한다.

---

핵심되는 말: 신경병증성 통증, mTOR, 전대상피질 (ACC), 라파마이신, 시냅스 가소성